Get the Stockscreener App
1.08
9.24%
-0.11
After Hours:
1.15
0.07
+6.48%
Clearmind Medicine Inc stock is traded at $1.08, with a volume of 90,632.
It is down -9.24% in the last 24 hours and down -25.52% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$1.19
Open:
$1.12
24h Volume:
90,632
Relative Volume:
0.30
Market Cap:
$1.94M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.0253
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-6.09%
1M Performance:
-25.52%
6M Performance:
-97.38%
1Y Performance:
-97.67%
1-Day Range:
$1.07
$1.15
1-Week Range:
$1.07
$1.27
52-Week Range:
$1.0495
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.08 | 2.14M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind gets safety board approval to continue AUD trial - Investing.com Nigeria
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval - Bitget
Clearmind (Nasdaq: CMND) moves CMND-100 alcohol-use trial into higher-dose stage - Stock Titan
Clearmind Medicine IncDSMB approves continuation of Phase I/IIa CMND-100 trial in AUD - marketscreener.com
Alcohol use disorder drug from Clearmind moves to higher-dose testing - Stock Titan
CMND Earnings History & Surprises | EPS & Revenue Results | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
CMND Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
What is Clearmind Medicine Inc.’s book value per shareAnalyst Downgrade & Stepwise Trade Signal Guides - mfd.ru
Is Clearmind Medicine Inc. stock trending bullishAnalyst Downgrade & Precise Entry and Exit Recommendations - mfd.ru
Moonage Media Review: Clearmind's MEAI and GLP-1Are These the Next-Generation Treatment for Weight Loss? - lelezard.com
Market Rankings: How do insiders feel about Clearmind Medicine IncWeekly Stock Report & Growth Focused Entry Reports - baoquankhu1.vn
Clearmind Medicine (CMND) trims second tranche of convertible note deal - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
What technical signals suggest for Clearmind Medicine Inc. stockJuly 2025 Intraday Action & Real-Time Volume Trigger Notifications - mfd.ru
How Clearmind Medicine Inc. (CWY0) stock trades pre earnings2025 Dividend Review & Expert Curated Trade Ideas - mfd.ru
Is Clearmind Medicine Inc. a turnaround storyWeekly Profit Analysis & Weekly Top Performers Watchlists - mfd.ru
Clearmind reports positive safety data from AUD treatment trial By Investing.com - Investing.com Australia
Clearmind reports positive safety results in AUD drug trial - Investing.com South Africa
Clearmind reports positive safety data from AUD treatment trial - Investing.com South Africa
Clearmind reports positive safety results in AUD drug trial By Investing.com - Investing.com Nigeria
Clearmind Medicine announces additional topline positive safety results reinforcing favorable profile of cmnd-100 in ongoing Phase I/Iia clinical trial - marketscreener.com
Clearmind Medicine stock falls after Phase I/IIa trial safety update By Investing.com - Investing.com South Africa
Clearmind Medicine stock falls after Phase I/IIa trial safety update - Investing.com Nigeria
Clearmind Medicine Announces Additional Positive Safety Topline Data From CMND-100 Study - Nasdaq
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial - The Manila Times
Clearmind Medicine Inc. Reports Positive Safety Results from Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine (CMND) Stock: Partners With Polyrizon to Advance Intranasal MEAI Therapy - parameter.io
Polyrizon climbs on Clearmind Deal - Baystreet.ca
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal - Investing.com India
Clearmind Medicine enters development agreement for intranasal formulation of proprietary nonhallucinogenic neuroplastogen MEAI - marketscreener.com
Polyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAI - TipRanks
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation - The Manila Times
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Inc. Partners with Polyrizon Ltd. to Develop Innovative Intranasal Formulation for MEAI in CNS Disorders - Quiver Quantitative
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic ... - Caledonian Record
Biotechs team up on intranasal, non-hallucinogenic addiction therapy - Stock Titan
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments - The Manila Times
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ ... - Caledonian Record
Breakouts Watch: Is Clearmind Medicine Inc a strong growth stock - baoquankhu1.vn
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):